Embryonic stem (ES) cells have the ability to reproduce themselves for a long period and differentiate into specific morphological and functional cells. The ES cells are an important material in developmental biology, genomics, and transgenic methods, as well as in potential clinical applications, gene therapy and tissue engineering. The pluripotent ES cells will be a valuable source in the treatment of numerous functional degenerative pathologies including Parkinson's disease (PD), which is characterized by progressive and selective loss of dopaminergic neurons in the midbrain substantia nigra. Thus, the most important for using ES cells in PD therapy is to direct their differentiation into dopaminergic phenotype to replace the degenerated cells. In this review, we summarize the neural differentiation directing protocol, transplantation results, and behavioral recovery of ES cells derived dopaminergic neurons in the therapeutic studies in PD animal models.
Introduction
Mammalian stem cells have the ability to prolongate proliferation and differentiate into several specialized cells that make up the tissues and organs of the body. Stem cells are classified by their sources into three classes: the embryonic stem (ES) cells that are derived from the inner cell mass of preimplantation blastocyst, 1−3 the embryonic germ cells that are derived from the primordial germ cells of the primitive genital ridge in the fetus, 4,5 and the adult stem cells that are isolated from differentiated tissues such as bone marrow, brain, blood, liver, pancreas, and skin.
6−8 The ES cells are believed to be most pluripotent, and under certain specific conditions, transplantation in various animal disease models are also reviewed. 22 The ES cells can serve as important tools in developmental biology, genomics, and transgenic methods, as well as in potential clinical applications such as degenerative medicine, traumatic disorder, gene therapy and tissue engineering. 23, 24 Differences Between Human,
Porcine and Murine ES Cells
Research has had remarkable results in inducing human ES cells differentiation into neuronal cells, 25, 26 pancreatic β cells, 27 and cardiomyocytes. 28 These results reveal the potential for the clinical application of human ES cells for the treatment of diseases such as spinal cord injury, 29 Parkinson's disease (PD), 30 diabetes, 31 and heart diseases. 32 Although human ES cells hold a promising future for treating degenerative disorders such as Parkinson's and Alzheimer disease, or in treating spinal cord injury, the preclinical research must be proven in suitable animal models to present its bio-safety and longterm efficiency of transplanted ES cells and/or their derived cells. Studies demonstrate the existence of differences between human ES and murine ES cells, suggesting that the information gained from murine ES cells, especially the gene expression profiles during neural differentiation, cannot be directly translated to human ES cells. 17, 33 Swine has been demonstrated as an excellent animal model in therapeutics development for various human diseases, including congenital heart disease, 34 hypertension, 35 organ transplantation, 36,37 pharmacology, and toxicology. 38, 39 In addition, the colony morphology of the porcine ES cells are very similar to human ES, and they are both feeder-dependent and refractory to leukemia inhibit factor. Porcine ES cells cluster into colonies sharing a flattened morphology of human ES but not mouse ES cells. 16 They both express octamer-binding transcription factor-4 (Oct-4), alkaline phosphatase (AP), stage specific embryonic antigen-3/4 (SSEA-3/4), tumor related antigen (TRA) 1-60, and TRA 1-81, but not the SSEA1 that is characterized by mouse ES cells. 40 Therefore, the porcine ES cells can provide an optimal preclinical animal model in the study of regenerative medicine in therapeutic approaches.
Parkinson's Disease and Animal Research Models
PD is a degenerative disorder that was first described by Dr. James Parkinson in 1817. The PD patients show shaking rigidity, balance problems and slowed movement in behavioral symptoms. Several major medical approaches of PD therapy, including pharmacological therapy with the dopamine precursors such as L-3,4-dihydroxyphenylalanine (L-dopa), Carbidopa-Levodopa (Sinemet) and Selegiline hydrochloride (Eldepryl). This DA-replacement treatment takes effects during early stages but is associated with devastating side effects, such as dyskenesia. 41 Further more, implanted Deep Brain Stimulation in subthalamic nucleus to stimulate with tiny electrical current can reduce the abnormal movement of PD patient. 42 Another surgical approach is to transplant fetal ventral mesencephalic cells in PD patients. 43 However, fetal cells transplantation has limitations with technical and ethical issues. 44 Due to the self-renewal capacity and multilineage developmental potential, ES cells can be ideal cell sources for cell replacement therapy. 45, 46 For the ES cells transplantation and functional recovery studies of PD, the nigrostriatal lesion and amphetamine-induced rotation behavioral analyses are well developed. The 6-hydroxy dopamine (6-OHDA) is injected into the medial forebrain bundle (nigrostriatal dopaminergic pathway) with the assistance of a stereotaxic instrument (anteriorposterior, AP = −4.4 mm; medial-lateral, ML = −1.2 mm; dorsal-ventral, DV = −7.8 mm; and AP = −4.0 mm, ML = −0.8 mm, DV = −8.0 mm). 47, 48 After lesioning, the animals demonstrate asymmetric rotations by using an automated rotometer (TSE, Germany) 49, 50 in response to D-amphetamine challenge are characterized as well-lesioned PD models and are used for ES cells transplantation into the striatum (AP = 0.0 mm, ML = −3.0 mm, DV = −5.0 mm). 48 
Neural Induction of ES cells
The efficiency for neural population conversion is the most important for stem cell replacement therapy in the field of neurological disorders. Although the low efficiency of neural differentiation derived from ES cells has been one of the major obstacles to overcome, 51 a significant improvement of neural lineages induction has been achieved by application of several morphogens such as all-trans retinoic acid (RA), sonic hedgehog (SHH), fibroblast growth factor (FGF), epidermal growth factor (EGF), bone morphogentic proteins (BMPs), and glial-derived neurotrophic factor (GDNF). 52−58 These molecules are essential for normal embryonic development and differentiation, 59 and are used as neurogenic stimulators of ES cells. 26, 55, 60 Perrier et al 57 develops an in vitro neural induction protocol of hESderived dopaminergic differentiation by co-culture with stromal cells MS5 and S2. A similar protocol also reports using co-culture with PA6 stromal cells 61 and PA6 cells overexpressing PA6-SHH. 62 A rapid protocol using the chemically defined culture system also allows human ES cells to differentiate into DA neurons by the addition of SHH and FGF-8, 63 or the recombinant human noggin, bFGF and dibutyrylcAMP, 64 or FGF8b and SHH. 65 Those derived cells exhibit the specific dopaminergic markers such as Lmx-1b (a transcription factor regulated the development of midbrain DA neurons), Nurr-1 and Ptx-3 (transcription factors expressed in midbrain DA neurons), Girk2 (a potassium channel expressed specific to DA neurons in the substantia nigra) and TH (a biosynthetic enzyme of DA).
62,64−66 These successful induction protocols provide powerful tools to control the development and function of ESderived midbrian DA neurons and makes ES cell therapy on PD promising in the future.
Porcine ES Cells in PD Therapy
In our laboratory, we establish a porcine ES cell line M215-3 derived from the blastocyst of the Livestock Research Institute Black Pig No. 1 (a topcrossing breed established from Taoyuan and Duroc pigs) ( Figure 1) ; we also derived three GFP-expressing ES cell lines from M215-3 by electroporation designated as pES/GFP + 10, 14-1, and 14-2 ( Figure 2 ). 40 They all maintain normal karyotype of 36 + XX and express the pluripotent markers Oct-4, AP, SSEA-3, SSEA-4, TRA 1-60, and TRA 1-81. For the study on ES cell therapy in neural regenerative disorders, we develop a directed differentiation protocol including a neural induction culture for 12 days and extending culture for 6 days. This induction allows us to attain more differentiated neural lineages that also provide a valuable yield on the process of differentiation of porcine ES cells into functional neurons ( Figure 3 ). Furthermore, the pigs offered some distinct advantages over other species and served as a better research model because they were immunologically and physiologically more similar to humans. This directed induction protocol will be helpful in further application of porcine ES cells in replacement medicine and in numerous functional degenerative pathologies. In our studies, we presented an in situ monitoring of these grafted cells with the assistance of a stereotaxic instrument, and their survival and development was determined every 15 days by two of live animal fluorescence optical imaging systems: the In Vivo Imaging System (IVIS 50; Xenogen Corp., Alameda, CA) was for the noninvasive tracking (Figure 4) , and the real-time images of grafted cells in recipient's brain was performed by ex vivo fibered confocal Cellvizio Imaging System (Cellvizio, Mauna Kea Technologies, Cambridge, MA, 
Figure 3
The porcine embryonic stem cell-derived neural cells showed a typical neural morphology with cell body and axons after directed differentiation.
USA) for invasive tracking during the 3 months of experimental period ( Figure 5 ). We also injected pES/GFP + cells and their derived cells of neural differentiation stages into the 6-OHDA lesioned PD rats. The in vivo cell growth and differentiation of the grafted cells, and the functional recovery of the PD animals were investigated in our study. 48 However, a major concern of ES transplantation is the tumorgenic potential if ES cells are to be applied clinically. 67 Consequently, the effort to determine those ES-differentiated cells posttransplantation in vivo aimed at monitoring the survival and development of grafted ES or ES-derived cells in PD therapy. The need for noninvasive or invasive monitoring of model systems has resulted in the development of small animal imaging technologies such as microcomputed tomography, micropositron emission tomography, magnetic resonance imaging, 68, 69 or fluorescence cystoscopy with hexyl aminolevulinate, 70 optical coherence tomography, 71 positron emission tomography, 72 and fibered confocal microscopy. 73 All of which are now capable of providing real-time images and obtaining the fate of ES cells for therapeutic purposes, 72, 74, 75 the course of cancer metastasis and therapy, 69, 76, 77 and embryo development. 78 To investigate the therapeutic potential in PD, we transplanted porcine ES cells into the SpragueDawley rat brain with the assistance of a stereotaxic instrument. Following 3 month of behavioral analyses after porcine ES cells transplantation, the functional behavior recovery analysis by amphetamine-induced rotation test indicated the grafted porcine ES-derived neuronal progenitors showed a decreased relative rotation rate and resulted in a functional recovery from PD behavioral defects. 48 The results of our study and several previous studies on PD therapy in the animal models are summarized in Table 1 . 45,46,48,61,62,65,67,72,79−92 Several studies indicate that the grafting of mouse or human ESderived DA neurons can reduce functional deficits significantly in PD animal models. 45,46,48,79,80−86 How ever, some studies show partial recovery from behavioral defects through the grafted mouse or monkey ES-derived cells. 72, 87 Some studies even show failure in improving rotational behavior deficits when animals were transplanted with human ESderived dopaminergic cells. 62, 67, 88 These inconsistent results imply the cell purification, cell population, induction protocol, survival and functional exhibition of grafted DA neurons are crucial for PD therapy. 48 The ES cell transplantation in the animal model of PD proves that this method is capable of relieving symptoms and offers real approach for cell replacement in regenerative diseases in the future. 6-OHDA: 6-hydroxy dopamine; AA: ascorbic acid; AADC: aromatic amino acid decarboxylase, mature dopaminergic neuronal phenotype marker; ALDH2: aldehyde dehydrogenase, an enzyme expressed by midbrain dopaminergic progenitors; BDNF: brain-derived neurotrophic factor; BM: bone marrow; DA: dopamine; DAT: dopamine transporter, mature dopaminergic neuronal phenotype marker; DDC: dopa decarboxylase, midbrain DA marker; EGF: epidermal growth factor; En1: engrailed-1, mid/hindbrain transcription factor; FGF and bFGF: basic fibroblast growth factor; Foxg1: forebrain transcription factor; GDNF: glial cell-derived neurotrophic factor; ITSFn: insulin-transferrin-seleniun fibronectin; Lmx1b: transcription factor regulating the development of midbrain DA neurons at early developmental stage; MFB: medial forebrain bundle; MPTP: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; NE: neuroepithelial cell; NeuN: neuronal nuclei marker; Nurr1: nur-related factor 1, transcription factors expressed in midbrain DA neurons; PA6: mouse stromal cell line; Pitx3: transcription factors expressed in midbrain DA neurons; SDIA: stromal cell-derived inducing activity; SFEB: serum-free embryoid body; SHH: sonic hedgehog; SN: substantia nigra; TGF: transforming growth factor; TH: tyrosine hydroxylase, mature dopaminergic neuronal phenotype marker; VMAT2: vesicular monoamine transporter, mature dopaminergic neuronal phenotype marker. 
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